|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation of property and equipment | |||||
| Gain on sale of fixed assets | |||||
| Abandonment and expiration of patents and trademark rights | |||||
| Amortization of patent and trademark rights | |||||
| Non-cash lease expense | |||||
| Amortization of financial obligation | |||||
| Equity-based compensation | |||||
| Non-cash gain on settlement of liability | |||||
| Loss on issuance of warrants | |||||
| Loss (gain) on sale of marketable securities | |||||
| Change in fair value of warrants | |||||
| Change in assets and liabilities: | |||||
| Funds receivable from New Jersey operating loss sales | |||||
| Prepaid expenses and other current assets | |||||
| Lease liability | |||||
| Other assets | |||||
| Accounts payable | |||||
| Other receivable | |||||
| Accrued expenses | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Proceeds from sale of marketable investments | |||||
| Proceeds from sale of marketable securities | |||||
| Purchase of marketable securities | |||||
| Purchase of property and equipment | |||||
| Proceeds from sale of property and equipment | |||||
| Purchase of patent and trademark rights | |||||
| Net cash provided by investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from sale of stock, net of issuance costs | |||||
| Proceeds from issuance of liability warrants | |||||
| Proceeds from issuance of common stock, net of issuance costs | |||||
| Repayment of debt obligation | |||||
| Proceeds from note payable, net of issuance costs | |||||
| Proceeds from issuance of equity warrants | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of year | |||||
| Cash and cash equivalents at end of year | |||||
| Supplemental disclosures of non-cash investing and financing cash flow information: | |||||
| Unrealized loss on marketable securities | |||||
| Unrealized gain on marketable investments | |||||
| Conversion of Series B preferred | |||||
| Repayment of debt obligation with shares | |||||
| Operating lease liability arising from obtaining right of use asset | |||||
| Cash paid for interest | |||||
Loading...